2seventy Bio and Bristol Myers Squibb Discontinue Study
2seventy bio, Inc. (NASDAQ:TSVT) and Bristol Myers Squibb have decided to stop enrollment in the Phase 3 KarMMa-9 study. This study aimed to evaluate how effective Abecma is when paired with lenalidomide maintenance for patients who have newly diagnosed multiple myeloma (NDMM) and showed less than optimal results after autologous stem cell transplant.
Financial Impact and Future Outlook
This isn't just a temporary hold; it's projected to save 2seventy bio over $80 million in the years ahead, which will help the company reach break-even status by 2025. The treatment landscape for NDMM has changed significantly, leading to a smaller number of eligible patients for this study compared to earlier estimates.
Despite this setback, there's positive news about Abecma’s performance. 2seventy bio forecasts a re-acceleration in U.S. revenues, expecting a significant 30% increase for the third quarter compared to the $54 million made in the second quarter. Demand for Abecma remains strong, evidenced by a surge of new patients undergoing apheresis, with expectations of double-digit growth from the previous quarter.
What is Abecma?
Abecma is an innovative therapy—a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. It’s specifically designed for adult patients suffering from relapsed or refractory multiple myeloma after they've undergone at least two previous treatment lines. Abecma is recognized for its distinct safety profile and impressive efficacy, particularly when used alongside effective bridging therapies.
Leadership Commitment
Chip Baird, the CEO of 2seventy bio, emphasizes the company's ongoing commitment to creating value for its stakeholders and improving patient experiences. Chief Medical Officer Anna Truppel-Hartmann also expressed gratitude for the contributions made by patients, families, investigators, and trial staff.
Collaborative Efforts in Drug Development
In their partnership, 2seventy bio and Bristol Myers Squibb share profits and expenses tied to the development, manufacturing, and sales of Abecma in the U.S. This collaboration is crucial as they work to make Abecma more accessible to patients with multiple myeloma.
The announcement shed light on their ongoing expectations and strategies regarding the financial performance of both companies.
Recent Company Developments
Recent updates from 2seventy Bio's Q2 2024 earnings call indicated significant progress regarding ABECMA. The company reported modest revenue growth, alongside a noteworthy increase in patients benefiting from apheresis treatment for ABECMA, offset by a significant reduction of $28 million in operating expenses. Collaboration revenue with Bristol Myers Squibb amounted to $4.4 million, along with a significant milestone: FDA approval that allows treatment for earlier line patients, greatly enhancing ABECMA's presence in the U.S. market.
Future Financial Projections
Looking down the road, 2seventy Bio plans to further cut operating expenses by 2025 and has revised its capital projections for 2024 to range between $40 million and $60 million. The company expects ABECMA to return to a growth trajectory soon. However, they chose not to provide specific revenue guidance for ABECMA or any updates on the timing for pipeline advancements led by Regeneron.
Market Reactions and Analyst Insights
Market reactions from analysts have been mixed. While some raised concerns about the lack of detailed revenue forecasts and pipeline updates, others remain optimistic about ABECMA, highlighting its favorable safety profile, expanding usage following FDA approval, and the significant benefits shown in clinical trials regarding progression-free survival.
Investing Insights into 2seventy Bio
With the recent decision to discontinue the KarMMa-9 study, gauging 2seventy bio's financial health and market position is crucial for investors. Recent data shows that 2seventy bio, Inc. has a market capitalization of around $246.68 million, positioning it firmly within the competitive biotech industry. Despite some forecasts suggesting falling sales this year, the firm’s liquid assets exceed its short-term liabilities, providing some financial steadiness amid strategic changes.
The stock has seen fluctuations but recently posted a strong return of 26.86% over the past three months, reflecting some investor confidence in long-term prospects, even with immediate challenges. Additionally, analysis suggests that the company may not reach profitability this year, as it hasn't been profitable over the last twelve months. This context encourages investors to proceed cautiously in their evaluations.
With a P/E Ratio of -1.55 and an adjusted P/E Ratio of -1.47 for the last twelve months up to Q2 2024, valuation metrics indicate the company's current unprofitability. Nevertheless, its price/book ratio stands at a relatively attractive 1.05, which could appeal to value-seeking investors.
Frequently Asked Questions
Why was the KarMMa-9 study discontinued?
The study was stopped due to changes in the treatment landscape for multiple myeloma, resulting in fewer eligible patients than anticipated.
What financial savings does this decision provide?
This strategic choice is expected to save 2seventy bio more than $80 million in the coming years.
What is the expected growth for Abecma?
The company forecasts a 30% increase in third-quarter revenue along with double-digit growth in new patients receiving treatment.
How does 2seventy bio plan to improve its financial health?
2seventy bio intends to further reduce operating expenses and is adjusting its net cash spend for 2024 to between $40 million and $60 million.
What is the collaboration relationship between 2seventy bio and Bristol Myers Squibb?
Both companies share profits and losses associated with the development, production, and commercialization of Abecma within the U.S.
